Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

by Philippe A Gallay, Udayan Chatterji, Michael D Bobardt, Zhengyu Long, Shengli Zhang, Zhuang Su
Published 2016-01-01

HCV core residues critical for infectivity are also involved in core-NS5A complex formation.

by Katarzyna Gawlik, James Baugh, Udayan Chatterji, Precious J Lim, Michael D Bobardt, Philippe A Gallay
Published 2014-01-01

Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms

by Brigitte Rosenwirth, Jean-Maurice Dumont, Grégoire Vuagniaux, Michael D. Bobardt, Philippe A. Gallay, Roger G. Ptak
Published 2013-03-01

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

by Philippe A Gallay, Michael D Bobardt, Udayan Chatterji, Daniel J Trepanier, Daren Ure, Cosme Ordonez, Robert Foster
Published 2015-01-01

Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice

by Jeremy R. A. Paull, Carolyn A. Luscombe, Alex Castellarnau, Graham P. Heery, Michael D. Bobardt, Philippe A. Gallay
Published 2021-08-01

HSV neutralization by the microbicidal candidate C5A.

by Lot de Witte, Michael D Bobardt, Udayan Chatterji, Freek B van Loenen, Georges M G M Verjans, Teunis B H Geijtenbeek, Philippe A Gallay
Published 2011-05-01